Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories rapid Diagnostics — International COVID-19 Testing Sales ($M) ($M)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, FY2024
175
Period ended Dec 31, 2024
Change on a year earlier
-41.5%
299 in FY2023
History
4 years
Since FY2021
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rapid Diagnostics — International COVID-19 Testing Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 175 | -41.5% | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 299 | -88.5% | SEC Filing (0001628280-25-002092) ↗ |
| FY2022 | Dec 31, 2022 | 2,603 | -4.4% | SEC Filing (0001628280-24-002009) ↗ |
| FY2021 | Dec 31, 2021 | 2,723 | – | SEC Filing (0001628280-23-001516) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Rapid Diagnostics — International COVID-19 Testing Sales ($M) ($M), annual FY2021–FY2024 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-rapid-covid-intl
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.